FDA Commissioner Marty Makary Resigns After 13-Month Tenor
Similar Articles
FDA Commissioner Marty Makary Removed After Pressure Over Vape Approvals
FDA Commissioner's Status Unclear Amid Reported Push for Removal
FDA Acting Drug Center Director Tracy Beth Hoeg Removed
FDA Authorizes First Flavored Vapes, Eases Enforcement on Some Products
House Removes Pesticide Lawsuit Shield From Farm Bill as White House Changes Surgeon General Nominee
Food and Drug Administration (FDA) Commissioner Marty Makary is stepping down after a 13-month term marked by internal turmoil and external pressure. His departure leaves a key health leadership role vacant as the agency faces vacancies in its drug and biologics centers. Kyle Diamantas, the FDA deputy commissioner for food, will serve as acting commissioner.
Facts First
- FDA Commissioner Marty Makary is resigning after a tenure of just over one year.
- The agency has experienced significant staff turnover, with senior career officials departing and its drug center cycling through multiple directors.
- Makary faced pressure from the White House over the approval of flavored vaping products, which were authorized days after a reported call from President Trump.
- He launched initiatives to streamline FDA reviews, including using AI and expediting reviews for medicines supporting 'national interests'.
- The Trump administration must now fill three Senate-confirmed health positions: FDA commissioner, CDC director, and surgeon general.
What Happened
Dr. Marty Makary, the commissioner of the Food and Drug Administration (FDA), is resigning from his position after a 13-month term. President Trump confirmed the departure on Tuesday. Kyle Diamantas, the FDA deputy commissioner for food, will serve as acting commissioner. The resignation follows months of complaints from health industry executives, anti-abortion activists, and vaping lobbyists. The Wall Street Journal reported that President Trump called Makary to scold him for not moving fast enough to authorize flavored vapes; the FDA authorized those products days after the reported call.
Why this Matters to You
The leadership change at the FDA could affect the pace and direction of drug and product approvals. The agency's internal vacancies and rapid turnover may slow reviews for new medicines and treatments. Policy shifts initiated under Makary, such as efforts to streamline clinical trials and reduce animal testing, may be revisited. Furthermore, the ongoing debate over drug pricing... directly impacts what you pay for prescription medications.
What's Next
The Trump administration must nominate a permanent successor for the FDA commissioner role, a position that requires Senate confirmation. Possible successors floated include former FDA commissioner Stephen Hahn and Brett Giroir. The administration also needs to fill the roles of Centers for Disease Control and Prevention (CDC) director and surgeon general. In the interim, acting commissioner Kyle Diamantas will lead an agency facing internal vacancies, which may affect its operational stability.